Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST: Bleomycin Electrosclerotherapy for Low-Flow Vascular Malformations
2025-524123-45-00Phase 2Authorised
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bleomycin in vascular malformation, sponsored by Institute of Oncology Ljubljana. Primary endpoint: Primary efficacy: lesion volume reduction at 3 months by MRI. Planned start Sep 2026; status: authorised.
02
Drugs
bleomycin
03
Conditions
vascular malformation
Beyond the preview
Go deeper on 2025-524123-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524123-45-00.